SCHEMBL2330307

SCHEMBL2330307

CCC(C)OP(=O)(O)CC(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPC1 O15118 2/20 0.42
ALDH1A1 P00352 4/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
CES1 P23141 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 2/20 0.38
PGR P06401 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778286 0.80 LMNA (0.41) LMNAPOLBKDM4EKMT2AMEN1
SCHEMBL4240925 0.78 KDM4E (0.46) LMNAPOLBKDM4ETDP1KMT2A
SCHEMBL5734845 0.78 POLB (0.57) LMNAPOLBKDM4ETDP1KMT2A
SCHEMBL28005057 0.76 POLB (0.56) LMNAPOLBKDM4ETDP1KMT2A
SCHEMBL1407856 0.76 TRPA1 (0.42) POLBKMT2AMEN1HPGDTSHR
SCHEMBL28005430 0.76 POLB (0.69) LMNAPOLBKDM4ETDP1KMT2A
SCHEMBL28005432 0.74 POLB (0.57) LMNAPOLBKDM4ETDP1KMT2A
SCHEMBL9055592 0.74 CYP2C9 (0.54) LMNAMAPT
SCHEMBL915155 0.73 FOLH1 (0.47) RAB9ASMN1; SMN2
SCHEMBL2714777 0.73 MMP1 (0.34) TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 LMNA 2625/4885POLB 2698/4885KDM4E 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.